Moreover, the consistent superiority of rosuvastatin over atorvastatin in driving caspase-3 activation across both colorectal cancer cell lines reinforces its potential as the more efficacious agent for therapeutic exploitation in inflammation-associated colorectal malignancy. Here, CASP3 is linked to colorectal cancer.